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1. Introduction  
Small-Cell Lung Carcinoma (SCLC) represents about 15% of all lung cancers diagnosed 
worldwide. Although its incidence is diminished in the last decades, SCLC continues to 
represent an almost fatal disease due to its propensity to local relapse and distant 
metastasis, despite initial responsiveness to therapies. Biological behaviour of SCLC has 
therefore lead to consider it as a systemic disease per se not amenable of surgical resection: 
the Veterans Administration Lung Study Group (VALSG) two-stage classification was in 
fact based on field irradiation criteria and has been applied to SCLC for long-time. 
The introduction of TNM staging system, the common recurrences of local disease despite 
initial complete response after chemo-radiation therapy, the lack of a valid maintenance 
therapy after remission or a second-line therapy after relapse renewed interest in surgery in 
a multimodal treatment setting. However, the second prospective randomized trial in 1994, 
did not confirm any significant advantage of surgery compared to chemo-radiation therapy 
and several retrospective studies published in the same years failed to provide strong 
evidences of surgery's benefits. Lack of homogeneity in design of clinical trials, which are 
mostly dated, patients selection and other confounding factors made results of meta-
analysis too much inconsistent to be added to guidelines; for these reasons, nowadays, 
surgery is recommended only in small peripheral nodules without nodal involvement 
(proven by invasive preoperative staging). 
Advances in comprehension of biological pathways underlying carcinogenesis in SCLC are 
the next steps that could deeply modify the approach to disease (patients selection and 
prognostic stratification, chemosensitivity and treatment modality) beyond the mere 
histology. Molecular profile should lead to identify subsets of tumours with more 
favourable prognosis, especially in terms of systemic control of disease, which is actually a 
major issue in SCLC; these subsets could be overlapped to NSCLC regarding to natural 
history of disease, making their treatment similar, including indication to surgery. 
The aim of this review is to analyze literature to deduce which has been, is actually and 
could be the role of surgery on overall survival and pattern of recurrence of patients affected 
by SCLC. 
www.intechopen.com
 
Lung Diseases – Selected State of the Art Reviews 
 
276 
2. Clinical background 
2.1 Epidemiology 
Small-cell Lung Carcinoma (SCLC) accounts for approximately for 13-15%% of all newly 
diagnosed cases of lung cancer worldwide (in United States, more than 220.000 new cases 
lung carcinoma were diagnosed in 2010, with about 160.000 cancer-related deaths 
[American Cancer Society, 2010]. 
More than 90% of patients with SCLC are elderly, current or past heavy smokers, and risk 
rises with increasing duration and intensity of smoking [Devesa et al., 2005]; rare cases have 
been reported in people who never smoked [Antony et al., 2010].  
Incidence of SCLC is decreasing compared to that of adenocarcinoma [Govindan, 2006]; this 
reflects the decreased prevalence of smoking in industrialised countries. However, the 
burden of disease is shifting to developing countries (Asia and Eastern Europe), where, on 
the contrary, an increase of incidence is expected in next years. Further investment in 
research against SCLC is therefore warranted.  
A revision in the WHO classification of lung cancers might also have contributed to 
incidence falling of SCLC, as some borderline cases previously described as mixed subtypes 
are now classified as NSCLC [Travis et al., 2004]. 
Median survival of untreated patients ranges from 2 to 4 months from diagnosis: historical 
data of untreated patients come from an old study of VALSG (Veterans Association of Lung 
Study Group) comparing cyclophosphamide to placebo. In IASLC (International Association 
for Study of Lung Cancer) database for staging project (the largest series of SCLCs reported), 
5-year survival rates were 38/21% for clinical stages IA/IB and 38/18% for clinical stages 
IIA/IIB, respectively. Considering only resected, fully staged patients, 5-years survival rates 
were 53/44% for p-stages IA/IB and 43/35% in p-stages IIA/IIB, respectively.  
2.2 Clinical presentation 
Two thirds of SCLCs present as peribronchial lesions with infiltration of bronchial 
submucosa. Extensive mediastinal lymph node metastases are a common finding at 
diagnosis; sometimes mediastinal involvement presents as “bulky” disease, causing 
superior vena cava syndrome. Only in 4-12% of cases SCLC presents as a peripheral “coin 
lesion” [Quoix et al., 1990]. 
Clinical presentation of SCLC is strictly related to stage and presence of paraneoplastic 
syndrome. Common symptoms are cough, wheeze, dyspnoea, haemoptysis for hilar 
localization. Symptoms may reflect direct involvement of chest wall, superior vena cava, 
oesophagus, recurrent nerve (pain, mediastinal syndrome, dysphagia, dysphonia) or the site 
of metastasis (brain, liver, adrenal glands, bone and bone marrow). SCLC is more frequently 
associated to paraneoplastic syndromes than NSCLC [Gandhi et al., 2006]. The most 
common are syndrome of inappropriate antidiuresis (15-40% of SCLC patients) and 
Cushing's syndrome (2-5% of SCLC patients), that can be responsible of infective 
complications during chemotherapy. Sometimes SCLC presents with dermatological 
abnormalities as acquired tylosis, trip palms, erythema gyratum repens [Master et al., 2010]. 
Occasionally SCLC is associated to dermatomyositis, hyperglycemia or hypoglicemia, 
hypercalcemia and gynecomastia. Neurological syndromes, that may precede diagnosis of 
SCLC by several months, are caused by cross-reaction of auto-antibodies and T-lymphocytes 
specific for common tumour epitopes and nervous components  [Darnell et al., 2003]. 
Antibodies directed against the P/Q- type voltage-gated calcium channel in the presynaptic 
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nerve terminal (expressed by 3% of SCLC) are responsible of Lambert-Eaton syndrome 
[Payne et al., 2010], that should be differentiated from miastenia gravis, rarely associated to 
SCLC. Similarly, paraneoplastic encephalomyelitis and paraneoplastic sensory neuropathy 
have been associated with antibodies directed against Hu proteins, a family of DNA-
binding proteins (<1% of SCLC patients) [Gultekin et al., 2000]; neurological symptoms are 
not always reversible with therapy. 
2.3 Diagnosis 
Although diagnosis of SCLC could be suspected on the basis of clinical and radiological 
findings, histo-patological diagnosis is required prior to establish the proper treatment.  
SCLC represents the extreme of spectrum of neuro-endocrine lung carcinomas and is 
defined as pure SCLC or combined SCLC if the non small-cell component accounts for at 
least 10%of burden disease. 
While pre-invasive and in situ lesions are frequently found in NSCLC, they are uncommon 
in SCLC [Kumar et al., 2005]. 
Samples can be obtained by bronchoscopy biopsy or fine-needle aspiration from primary 
tumour, lymph nodes or other metastatic sites. Since tumour shows propensity to spread 
through tunica submucosa, superficial bronchoscopic biopsy or brush may be falsely 
negatives. Colliquative necrosis can sometimes hamper diagnosis, especially for cytological 
samples; however there is a good interobserver agreement among pathologists for 
differential diagnosis with NSCLC. Immunohistochemistry is used in difficult cases:  less 
than 10% of SCLC tumours are negative for all neuroendocrine markers (chromogranin, 
synaptophysin, and CD56. Positivity for TTF-1 and cytokeratins helps to distinguish them 
from lymphomas and other small-cell tumours [van Meerbeeck et al., 2011] 
2.4 Staging 
Historically, SCLC had been classified according to the Veterans Administration Lung Study 
Group (VALSG). In 1957 the VALSG created a dichotomous staging system that took into 
account the aggressive behaviour of SCLC and the standard of care at that time. This 
classification underlined the highest importance of radiation therapy and allowed a better 
selection of patients for this kind of treatment.  
The Limited Disease (LD) was characterized by a tumour volume encompassed in one 
radiation portal (30% of cases): all that was not comprised in one radiation portal was 
classified as extensive stage (ED), including malignant pleural effusion and haematogenous 
metastases. [Zelen et al., 1973]. In 1989 the International Association for the Study of Lung Cancer 
modified the VALSG staging including all non-metastatic patients in the limited stage 
[Stahel et al., 1991] (Tab.1).  
More recently, in 2007, the IASLC based on a retrospective analysis of survival of 8088 
patients with SCLC recommended the TNM classification system also for SCLC [Shepherd 
et al., 2007]. This suggestion comes from the evidence of significantly worse survival of 
patients with limited-stage disease and N2-N3 lymph node involvement, than for those with 
N0-N1 lymph node involvement. Patients with pleural effusion without extrathoracic 
metastasis showed a survival intermediate between stage III and stage IV. In the TNM 
classification patients with cytology-negative pleural effusion are classified as having stage 
III disease. This classification is used less frequently in clinical practice because it relies on 
surgical confirmation for its accuracy and patients with SCLC seldom present at a stage for 
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which surgery is appropriate (in IASLC database only 349 patients out of 12.620 affected by 
SCLC were resected, representing only 2,8%). 
 
VALSG staging TNM staging 
Limited Disease: disease encompassed 
within a tolerable radiation therapy portal 
 Tumour confined to one hemithorax 
 Involvement of ipsilateral and 
contralateral mediastinal nodes 
 Involvement of ipsilateral 
supraclavicular nodes 
 Ipsilateral pleural effusion 
From IA to IIIB 
Extensive Disease: any other IV 
Table 1. Comparison between VALSG and TNM staging 
Considering the therapeutic options (chemotherapy and radiotherapy) representing, to date, 
the standard of care, it could be argued that the more precise staging of SCLC using the 
TNM system does not provide extra benefits to select the treatment modality. However 
TNM has been shown to be prognostic of outcome [Micke et al., 2002], and a more precise 
definition of nodal involvement may be relevant for radiation treatment. Moreover, surgery 
for limited disease (T1-2, N0, M0) is nowadays considered a valid therapeutic option 
[Varlotto et al., 2011]. For these reasons clinicians and cancer registrars recommend to 
classify SCLC with the TNM staging system [Shepherd et al., 2007]. This recommendation is 
particularly strong for those trials in LD addressing thoracic and prophylactic cranial 
irradiation questions and those that include a surgical treatment arm [Vallieres et al., 2009]. 
In the future a better definition of N stage is needed and prognostic difference in patients 
with or without cytology-positive pleural and/or pericardial effusions must be addressed. 
To assess the extent of disease, which remains the main prognostic factor, several staging 
tests are available; their execution sequence should be guided by the patient’s signs and 
symptoms at presentation and the availability of the diagnostic tests. Staging should be 
accurate and fast, considering the rapid growth of SCLC. Staging work-up should include 
full medical history, physical examination, chest X-ray, hematology and chemistry panels 
including differential blood count, liver and renal function tests, lactate dehydrogenase 
(LDH) and sodium levels (hyponatremia, due to ectopic production of antidiuretic hormone 
or atrial natriuretic peptide, is observed in up to 15% of patients), pulmonary function tests, 
and contrast-enhanced CT of the chest and upper abdomen. SCLC displays the propensity 
for early distant metastases to liver, bones, adrenal glands, and above all brain. Therefore, in 
patients with suspect for distant metastases, additional tests may include bone scintigraphy, 
CT scan with intravenous contrast or MRI of the brain, and bone marrow aspiration and 
biopsy. Bone marrow is involved in 15 to 30 percent of patients at presentation, but it 
represents rarely a solitary site of metastatic disease (2 to 6%). Bone-marrow infiltration 
should be suspected in presence of an isolated rise in lactate dehydrogenase (LDH) 
concentration or blood counts indicating otherwise unexplained anemia or a 
leucoerythroblastic response or if bone scan is positive [Campling et al., 1986]. CT or MRI of 
the brain are recommended if chemo-radiation with curative intent is under consideration. 
In one report, the prevalence of brain metastases was 10% with CT and 24% with MRI. In 
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this series all CT-detected brain metastases were symptomatic, whereas 11% of those 
detected by MRI were asymptomatic [Seute et al., 2008]. Chest CT scan, abdominal CT scan, 
brain MRI and bone scintigraphy are mandatory in the evaluation of patients amenable to 
surgery [Koletsis et al., 2009]. Fluorodeoxyglucose (FDG) uptake is usually high in SCLC, 
leading to a sensitivity of nearly 100% but its routine use in SCLC remains controversial 
[Thomson et al., 2011]. PET is, anyway, useful to plan radiotherapy in some countries [Van 
Loon et al., 2010]. Pathological confirmation is still required for PET-detected lesions that 
could result in upstaging, in particular if radical resection could be offered. The role of 
combined fluorodeoxyglucose PET (FDG-PET) and CT scanning is yet to be completely 
defined but, if available, it may be useful to improve the accuracy of staging by the detection 
of mediastinal nodal and occult distant metastatic spread. In patients who present with 
pleural effusion, in the absence of extrathoracic disease, cytopathologic confirmation of 
tumour involvement is needed. 
With improvements in staging through the use of PET/CT and magnetic resonance imaging 
(MRI), more patients are found to have ES-SCLC: the ratio of LS-SCLC to ES-SCLC was 
formerly 1:1 and is now 1:3 as more subtle lesions, such as silent adrenal and brain 
metastases, are identified. 
If extensive disease is detected by one test, further staging can be omitted, although bone 
scintigraphy may be used to identify symptomatic lesions amenable of palliation 
radiotherapy and brain CT/MRI could be performed or repeated in patients who respond to 
treatment in order to plan a brain irradiation of symptomatic lesions or to plan PCI in 
absence of metastasis (since PCI has been extended to ED-SCLC responsive to primary 
treatments) 
2.5 Prognosis 
Stage is the major prognostic factor of survival but some other prognostic factors have been 
identified: performance status, weight loss, sex and some laboratory tests (CEA, LDH, NSE, 
hypoalbuminemia, elevated alkaline phosphatase). No histological or molecular features 
have been validated yet. Several algorithms have been elaborated for predicting survival but 
the reliability for individual patients remains poor. Paraneoplastic syndromes are more 
frequently found in patients with limited-stage SCLC and they are considered positive 
prognostic factors. 
3. Historical background of SCLC 
SCLC was firstly recognized by Barnard in 1926, who noted that “oat-cell sarcomas of the 
mediastinum” were metastatic carcinomas of the lung instead.  
In the 85 years of SCLC life, some milestones should be reminded: 
1959: Pathogists recognized SCLC as a separate entity among carcinomas of the lung and 
Azzopardi defined six features of cells at light microscopic examination [Azzopardi, 1959] 
1963: VALSG introduced the 2-stage system for SCLC 
1969: British Medical Research Council reported better survival of radiotherapy arm versus 
surgical arm in the first clinical randomized trial on SCLC [Miller et al., 1969]. 
Cyclophosphamide showed to be effective against lung cancer [Green et al., 1969] 
1979: Medical Research Council showed advantage in survival with combination of 
chemotherapy (cyclophosphamide) and radiation therapy compared with radiation alone in 
LD-SCLC [Medical Research Council Lung Cancer Working Party, 1979] 
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1982: Shields re-evaluated surgery as initial treatment in SCLC after introduction of TNM 
staging system [Shields, 1982] 
1987: Adding RT to chemotherapy improved survival in LD-SCLC [Perry et al., 1987] 
1989: The International Association for Study of Lung Cancer (IASLC) was revised for the 
first time by its introduction the Veterans Administration Lung Study Group staging system 
[Stahel, 1989] 
1994: Lung Cancer Study Group published results of the first (and unique, so far) 
perspective randomized trial in LD-SCLC comparing surgery to RT after induction 
chemotherapy: Authors concluded that surgery offered no advantage in terms of either 
survival or local control of disease. 
1995-1999: Prophylactic Cranial Irradiation (PCI) showed to improve overall and disease-
free survival in selected patients (responders to first-line treatments) [Aupérin et al., 1999] 
1999: studies of dose fractionation of RT demonstrated that twice-daily administration was 
superior compared to once-daily in terms of local control and overall survival [Turrisi et al., 
1999] 
Combining this dates we can schematically recognize three periods.  
3.1 The “Surgical Era” (early 1900-1960s) 
The dramatic increase of tobacco consumption in early 900’s produced a sharp increase of 
incidence of SCLC; on the other hand, prevalence of pulmonary tuberculosis and chest 
wounds during World Wars promoted advances in thoracic surgery and lung resections. 
Surgery was considered the standard of care for Small-Cell as well as Non small-cell lung 
cancer. However high rates of recurrence (both local and distant), even after apparently 
complete resection, were observed. Results published by British Medical Council Group in 
first clinical prospective trial randomizing patients affected by SCLC to either surgery or 
thoracic radiation therapy reported the slight advantage in survival of RT arm. This was 
enough to abandon surgery at least for primary therapy for SCLC. Dichotomous staging by 
Veterans Administration Lung Cancer Study Group (1968) reflected and anticipated the 
centrality of RT as primary treatment for local control of disease 
3.2 The “advent of Chemotherapy” (1960s-1980s) 
Few years later report of British Medical Council, the pathology study conducted by 
Matthews in autopsies of patients deceased within 30 days of attempted curative resection 
showed that SCLC had, in almost all patients, microscopic but widely metastatic disease 
[Matthews et al., 1973]. This enforced the importance of accurate staging of disease and 
promoted the need of systemic control of disease. The chemosensitivity of SCLC was first 
recognized in 1940s when nitrogen mustard (methyl-bis-B-Chloro-ethyl amine 
hydrochloride) demonstrated capability of inducing tumour regression in more than 50% of 
patients. Despite a large amount of active drugs towards SCLC, it was perceived quite early 
that single-agent regimens were associated to frail remissions and high rates of precocious 
recurrences. In 1970s combination chemotherapy, mainly based on cyclophosphamide 
showed dramatic responses, even in very incapacitated patients, although long term 
disease-free survival remained disappointing and natural history of disease did not seem to 
change. Chemotherapy became the standard of care also in limited disease when Medical 
Research Council demonstrated the advantage of a combination of cyclophosphamide and 
radiation compared with radiation alone. During the 1970s thoracic radiation was relegated 
to an adjuvant, “consolidative” role in LD-SCLC.  
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3.3 Evolution of combined modality treatment (1980s-today) 
The last period could be considered as “quiescent”: no tools against disease proved to be 
revolutionary and efforts were made towards integration of multimodal approach. 
Paradigms and flow charts of treatment did not reflect the chronological sequence of most 
important studies but rather controlled studies and consensus expressed by expertise panels 
of Authors. Etoposide and platinum became from 1980s the first-line treatment. An 
important study from National Cancer Institute (NCI) in 1976 firstly tested a very aggressive 
protocol involving simultaneous irradiation of brain, primary tumour and mediastinum and 
concomitant CAV chemotherapy (cyclophosphamide/doxorubicine/vincristine). Despite 
unacceptable toxicity (radiation pneumonitis in 38%, mielodepression with fatal sepsis in 
24%), this regimen showed the best results, never reached before (nearly 100% complete 
remissions, 80% of long term survival) [Greco et al., 1979]. This work firstly recognized the 
importance of tumour repopulation by clones of cells whose resistance was allowed by 
sequentiality of treatments. Efforts were made in order to minimize tissue interaction 
without compromising delivery of both radiation and chemo-therapy: timing of radiation 
therapy [Perry et al., 1987] and dose fractioning [Turrisi et al. 1999] were largely studied by 
various Authors.  
In this period surgery revived with first report from Shields and coll. who concluded that 
primary surgery and adjuvant chemotherapy could be offered to patients with SCLC in 
early stages (i.e. T1N0). A large number of subsequent studies (discussed in the chapter) 
reported favourable long-term survival after surgery with improved local control of disease: 
one of the most remarkable experience was that of Toronto Group [Shepherd, 1983]. 
Undoubtedly, advances in both imaging and invasive staging tools (spiral CT, PET/CT, 
FNA-EBUS) lead to a more precise stratification of disease, allowing selection of patients in 
really “limited” disease amenable for radical resection. Application of TNM staging as used 
for NSCLC eliminated one of the barriers that divided SCLC and NSCLC and contributed to 
better define prognosis of patients previously classified as having Limited Disease (an 
heterogeneous stage ranging from isolated coin lesion to extensive hilar mass with 
supraclavicular node metastasis). 
Times were mature for another clinical perspective randomized trial involving surgery: it 
was started by Lung Cancer Study Group in 1983 and ended in 1994. Results again excluded 
a benefit of surgery even on a multimodal approach, but did not prevent further Authors to 
report their retrospective experiences on surgically resected SCLC, criticizing at the same 
time this study. 
Main changes of treatment modalities in SCLC are summarized in Fig. 1 
 
 
     1920s      1960s                    1970s           1980s            1990s                     2000s 
Hyperfractionated 
radioptherapy 
Surgery 
Cisplatin-based 
chemotherapy 
Concurrent 
chemoradiation 
for LD 
Radiation 
therapy 
Prophylactic 
cranial irradiation 
(LD) 
Second-line 
chemotherapy 
with topotecan
Prophylactic 
cranial irradiation 
(ED) 
Cyclophosphamide 
based chemotherapy 
 
Fig. 1. Evolution of treatment modalities through decades 
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4. Current guidelines for treatment (NCCN/ACCP)  
It should be noted that guidelines for the treatment of SCLC are based on review of a 
literature that lacks of big randomized prospective trials and is heterogeneous regarding to 
kind of treatment, timing, endpoints and selection of patients. 
The National Comprehensive Cancer Network (NCCN) has recently developed a review of 
its guidelines, declaring that every recommendation for SCLC has to be considered category 
2A, because they are “based upon lower-level evidence” but “uniform NCCN consensus 
that the intervention is appropriate” (see Table 2). [NCCN Clinical Practice Guidelines in 
Oncology] 
 
 
Table 2. NCCN category of recommendation. 
The American College of Chest Physicians (ACCP) in 2007 produced a systematic literature 
review resulting in evidence–based guidelines, graded upon the “ACCP grading system for 
guideline recommendations” 
Both documents debate on diagnostic and therapeutic options for SCLC and are quite 
similar in recommendations, except for the use of PET (not yet standardized in 2007 ACCP 
guidelines) and for the choice of staging system (NCCN recommending the use of the new 
TNM instead of Veterans Administration Lung Study Group classification). 
Guidelines for treatment have a key point in the use of platinum-based chemotherapy plus 
radiotherapy for all fit patients (Performance Status 0-2) with limited stage disease, followed 
by Prophylactic Cranial Irradiation (PCI); topics of discussion are timing of radiotherapy 
(concurrent versus sequential, early versus late), volume, dose and fractionation of radiations, 
treatment of unfit-elderly patients, maintenance and second line chemotherapy and surgery. 
Cisplatin has to be preferred to Carboplatin in combination with Etoposide in first line 
treatment; in phase III randomized trials, Irinotecan was substituted for Etoposide in 
combination with Carboplatin in advanced disease with mild improve in survival and thus 
being added to guidelines as an option for patients with extensive-stage disease. In these 
patients, where the treatment of choice is chemotherapy alone with initial response of about 
60-70% but median survival of 9-11 months due to early relapse, maintenance or 
consolidation chemotherapy beyond 4 to 6 cycles is currently not recommended outside 
clinical trials (grade of recommendation IB); likewise, the introduction of a third agent 
(alkylating agent with or without anthracycline) showed minor advantage in duration of 
response without improving survival and carried greater cumulative toxicity. The use of 
cytochine or anti-angiogenetic agents (i.e. Bevacizumab) is not currently recommended in 
first line treatment, even though randomized phase III trials are currently running. 
Second line treatment is generally a single agent therapy, administered with an interval of at 
least 3 month since initial therapy (otherwise disease has to be considered refractory or 
resistant) and should be given until 2 cycles beyond best response, progression of disease, 
development of major toxicity.  
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The addition of thoracic radiotherapy has improved survival in patients with limited stage 
disease (grade of recommendation 1A); staging of SCLC actually involves relationship 
between extension of disease and radiation port field. As far as timing is concerned, early 
(within 30 days to 9 weeks since the beginning of chemotherapy) concurrent chemo-
radiotherapy is recommended for patients with limited-stage disease (grade of 
recommendation 1A). Hyper-fractionation of radiation dose has not yet being correctly 
compared to once-daily administration in available trials, according to NCCN review of 
literature. 
PCI given after completion of chemotherapy in a low dose per fraction causes less 
neurological toxicity and prevent the emergence of brain metastasis, both in limited and 
extensive stage disease; it is recommended for fit patients who achieve a complete or partial 
response to initial treatment (Grade of recommendation 1B). 
Radiotherapy is also recommended in relapse for palliation of symptoms. 
The European Society of Medical Oncology (ESMO) in the 1st consensus conference in lung 
cancer stated guidelines for diagnosis, treatment and follow up of SCLC, underlying the 
absence of randomized trials comparing surgery with concurrent chemo-radiotherapy. 
Nevertheless, with grade of recommendation III D, surgical resection may be considered for 
very limited disease (T1-2, N0), only after histological confirmation of N parameters by 
mediastinoscopy, followed by PCI. 
ACCP guidelines stress the importance of invasive mediastinal staging, with grade of 
recommendation 1A. NCCN guidelines specify that lobectomy has to be preferred if 
resection is performed and that adjuvant chemotherapy alone is recommended for patients 
without nodal metastasis, while mediastinal RT has to be added in case of nodal 
involvement (Fig. 2) 
5. Studies regarding surgery in SCLC 
Except from those by British Medical Council and Lung Cancer Study Group, all studies 
focused on surgery in SCLC are retrospective or prospective non-randomized, so 
conclusions should be interpreted cautiously.  
However, also those phase III trials have been criticised on several points.  
The British Medical Council study, dated 1963, did not include patients with peripheral lung 
lesions, since  preoperative evaluation and diagnosis were made using rigid bronchoscopy 
available at that time; secondly, rate of complete (R0) resection was low (approximately 
50%) compared to resections for NSCLC; finally, staging was performed without modern 
tools, like contrast CT-scan or PET, nor histological confirmation by mediastinoscopy was 
obtained. So it is likely that a remarkable number of patients with occult intrathoracic and 
extrathoracic disease was included in the study and randomized to surgery, compromising 
the long term survival results. 
Twenty years later, after advent of chemotherapy as standard primary treatment, times 
were mature for another randomized trials, set up by Lung Cancer Study Group in 1983. 
Eligibility criteria include LD stage, according to VALSG staging: this means that also 
patients with clinical evident mediastinal adenopaties were included in the study. 
Conversely, patients with peripheral nodules and normal bronchoscopy were specifically 
excluded from the study. Induction therapy was quite heterogeneous (anthracycline based 
regimen) and only 144 of 340 patients (42%) accrued in the trial were randomized (68 to 
surgery arm and 76 to radiotherapy arm). Six patients randomized to surgery refused  
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SCLC or
mixed SCLC/NSCLC on biopsy
OR
cytology of primary metastatic site
LIMITED DISEASE
Any T (except T3-T4 due to
multiple lung nodules that not fit
in a tolerable radiation field)
Any N
M0
EXTENSIVE STAGE
Any T
Any N
M1 a/b
PATHOLOGICAL MEDIASTINAL
STAGING NEGATIVE
PATHOLOGICAL MEDIASTINAL 
STAGING POSITIVE 
OR 
MEDICALLY INOPERABLE
Lobectomy and mediastinal
lymph node dissection
PS 0-2: chemotherapy and 
cuncurrent thoracic radiotherapy
PS 3-4: chemotherapy ± RT
N0: chemotherapy
N+: chemotherapy ± mediastinal RT
IF
COMPLETE OR 
PARTIAL RESPONSE: 
PROPHILACTIC
CRANIAL IRRADIATION
Without localized symptomatic sites
or brain metastasis:
COMBINATION CHEMOTHERAPY
With localized symptomatic sites
or brain metastasis:
CHEMOTHERAPY ±
RT on symptomatic sites
 
Fig. 2. NCCN clinical practice guidelines 
thoracotomy and, on the contrary, eight patients requested surgical intervention and 
received off-randomization surgery, representing a significant cross-over (10%) between the 
two arms. Moreover, few other data should be pointed out: only 65% of patients responded 
to induction chemotherapy, in 17% of patients assigned to surgery only exploratory 
thoracotomy was performed and, above all, the high proportion of patients included with 
bulky N2 or N3 nodal metastasis (who unlikely achieved a complete mediastinal 
downstaging). Interestingly N status and post-treatment clinical stage did not influence 
resectability (a result correlated with clinical understaging).  
The conclusion of the study was that surgery did not add any benefit neither in terms of 
survival nor of pattern of recurrence. 
The same results were anticipated in a retrospective study of 1985 based on 33 operated 
patients compared to 46 patients who fulfilled criteria of operability and resectability but 
were treated with non-surgical management. However microscopic or macroscopic residual 
disease was left in half of patients, suggesting that clinical staging was not so accurate in 
predicting resectability of disease [Østerlind, 1985] 
Considering these weak points, rejection of surgery did not discourage several Authors, 
which continued to report good results with surgery combined to either induction or 
adjuvant chemotherapy and radiotherapy in some cases. 
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Rostad et al. analyzed 2442 patients with SCLC in a national survey in Norway, 38 of which 
were surgically resected (25 received adjuvant therapies). For stage I addition of surgery to 
conventional treatments (chemo-radiation) improved 5-year survival rate from 11.3% to 
44.9%, so Authors concluded that patients with resectable disease in stage I should be 
referred to surgery [Rostad, 2004]. 
The same conclusion is reported by Leo and Pastorino in their review [Leo & Pastorino, 
2003] for T1-2N0M0 patients which can be treated by surgery and adjuvant chemotherapy, 
while patients in stage II-III should undergo surgery only in the context of clinical trials. 
Rea et al. reported a 32% overall survival in 104 patients with SCLC surgically resected, 
despite a remarkable percentage of stage III (43.3%), which resulted as a major negative 
prognostic factors [Rea, 1998] 
Brock et al reviewed their institutional experience of 1415 SCLC among whom 82 (6%) 
underwent surgery with curative intent from 1976 to 2002 [Brock, 2005]. Surgery was 
accompanied by induction or adjuvant chemotherapy in 77% of patients. Authors found a 5-
year survival of 85.7% for stage I SCLC (similar to that historically expected for completely 
resected stage I NSCLC without adjuvant chemotherapy). Favourable prognostic factors 
were early stage, lobectomy as surgical procedure, female gender and date of intervention 
after 1987 (a surrogate marker for availability of platinum based chemotherapy). Pattern of 
recurrence was not reported in this study, however Authors concluded that lobectomy plus 
platinum based chemotherapy is a feasible option yielding excellent results in T1-T2N0-M0 
SCLC. 
High 5 years survival rate was reported also by Tsuchiya in a retrospective series of patients 
treated with a similar protocol [Tsuchiya, 2005]. Interestingly, Authors reported only 10% of 
local failure after surgery, which is lower than commonly reported after chemo-radiation 
therapies alone. 
Badzio and coll. in a retrospective series of patients treated with surgery or non-surgical 
management reported a significative improvement in survival in surgical resected patients 
(22 months Vs 11, P<0.001) [Badzio, 2004]. The control group of patients treated with chemo-
radiotherapy was built using pair-matched case-control according to main prognostic 
factors, stage and resectability; moreover diagnosis of surgical treated patients was 
established only postoperatively, thus minimizing some bias related to selection of patients. 
In 2006 the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of 
Pneumology and Thoracic Surgery (GCCB-S) presented a multicenter study on 47 patients 
with SCLC out a total of 2994 lung cancers resected [Gomez de Antonio, 2006]. Thirty-three 
% of patients had incomplete resection suggesting that the criteria for surgery were not 
predictable enough for resectability. The routine use of mediastinoscopy (performed only in 
19% of cases) might have identified some of the patients whose clinical staging was 
underestimated and which added to low rate of respectability. Moreover a low proportion 
of patients received adjuvant treatments. These factors accounts for an overall survival 
which does not exceed that reported in literature for patients with possibly more advanced 
stage managed with chemo-radiotherapy. 
Recently, Schreiber and coll. analyzed patients included in the Surveillance, Epidemiology 
and End Results registry (SEER), which is the cancer registry representative of United States 
[Schreiber, 2010]. Among 14.179 patients affected by SCLC coded as localized (T1-2Nx-0) or 
regional disease (T3-4Nx-0), 863 (6%) had undergone surgical resection, making them one of 
the larger population based cohort ever reported in literature. Overall 5-year survival rates 
were 26.3 Vs 9.3% (P=0.01) in favour of surgery with median survival of 22 Vs 12 months, 
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respectively. Advantage of surgery to survival was much more substantial in N0 patients 
(median survival 40 Vs 15 months), which on the other hand did show benefit from addition 
of PORT (Post-Operative Radiation Therapy). These data seem to suggest that radical 
surgery alone could be adequate for local control of disease and, conversely PORT may be 
detrimental for survival. Another retrospective analysis of SEER database conducted in 2010 
and focused only on stage I confirmed reasonable outcome in patients who underwent 
lobectomy without PORT [Yu et al., 2010]. Unfortunately both studies, although based on 
large population, lack of data concerning chemotherapy, margins of resection, pathologic 
confirmation of diagnosis and performance status (not recorded in SEER database). 
 
Study Number of 
patients  
Treatment Modality Local 
recurrence 
5-year survival 
Fujimori, 1997 22 PE x 2/4  S 5% Cumulative: 66.7% (3-year) 
Stage I-II: 73.3% (3-year) 
Stage IIIA: 42.9% 
Lucchi, 1997 127 S (15) 
S  CT (RT) (92) 
CT  S  CT (15) 
4.1% 
(10.6% 
local+dista
nt) 
Cumulative:  22.6% 
47% in stage I 
0% in N2 patients 
0% with surgery alone 
Eberhardt, 
2003 
46 Stage I-IIA: PE x 4  S 
Stage IIB-IIIA: PE x 3 
 CTRx (HfRTx)  S 
0% Cumulative: 39% 
 
Badzio, 2004 134 S  CT (67) 
CTRx (67) 
5% 
15% 
Cumulative: 27% (4% 
CTRx) 
Stage IA: 59% 
Rostad, 2004 38 S 
S  adjuvant 
n/a Stage I: 44.9% 
Brock, 2005 82 (CT)  S  (CT)  Stage I: 58% 
Stage II: 18% 
Stage III: 23% 
Stage IV: 0% 
Tsuchiya, 2005 62 S  PE x 4 10% Stage IA/IB: 73/67% 
Stage II: 38% 
Stage III: 39% 
Granetzny, 
2006 
95 S  CTRx (Stage I) 
CT  S  CTRx 
(Stage III) 
n/a Median survival (months) 
31.3 (Stage I) 
31.7 (Stage III – 
downstaged) 
12.4 (Stage III – not 
downstaged) 
Gomez De 
Antonio, 2006 
47 CT  S (3) 
S  CT (30) 
S (14) 
n/a Cumulative: 26% 
R0 resection: 31% 
Stage I: 36% 
Schreiber, 
2009 
863 S 
S  RT 
CT data n/a 
 Cumulative: 34.6% 
Stage I: 44.8% 
Stage II-III: 26.3% 
S: surgery, CT: chemotherapy, CTRx: chemoradiation therapy, PE: Platinum-Etoposide, HfRTx: 
Hyperfractioned Radiation therapy 
Table 3. Some of the recent trials supporting the role of surgery 
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A current year report on a small series of patients (28) underlines the low rate of local failure 
(3/28) after surgery compared to distant (especially brain) metastasis, which confirms the 
role of PCI [Ogawa et al. 2011] 
5.1 Rationale of surgery in SCLC 
As pointed out by Anraku and Waddell [Anraku, 2006] in their review, rationale of surgery 
can be can summarized in the following clinical presentations. 
 Small peripheral coin lesions: typical or atypical carcinoids may be misdiagnosed as 
SCLC since their diagnosis is often made on cytological samples obtained by either 
trans-thoracic fine needle biopsy or trans-bronchial biopsy by bronchoscopy 
 Combined histology tumours: definitive histology of tumours initially diagnosed as 
pure SCLC reveals a Non Small-Cell component in 11-25% [Asamura, 2006]. 
Percentages are higher in surgical reports possibly due to the fact that combined SCLC 
tends to arise peripherally and resection is feasible more frequently and because a 
larger amount of tissue for individuation of both components is available with surgical 
specimen [Mangum, 1989]. Although prognosis is mainly determined by the 
aggressiveness of Small-Cell component, the Non Small-Cell one may fail to 
chemoradiation protocols commonly used against SCLC being responsible of weak 
responses or early relapses. 
 Early stages (T1-2N0M0) benefit of surgical resection in terms of improved local control 
of disease: first site of recurrence (which occurs in approximately 50% of cases after 
concurrent chemo-radiation protocols [Turrisi, 1999]) is the tumour bed site followed by 
hilar/mediastinal lymph nodes, even in patients who achieve complete pathological 
remission [Elliott, 1987]. Adjuvant radical resection (i.e. with R0 margins) after 
induction chemoradiotherapy has shown local control of disease in almost all cases and 
this is reflected in a slight advantage in long-term survival [Eberhardt, 2003]. Table with 
local recurrences and survival 
 If general criteria for operability and resectability are met, adjuvant “salvage” surgery 
is preferable in cases of a chemotherapy resistant tumour or early local relapse (usually: 
3 months) after an initial response, compared to second-line therapies which are often 
uneffective against SCLC. In their report, the Toronto Group identified a small subset of 
patients without node metastasis that benefit from salvage surgery). A second biopsy, if 
feasible, is worthy to be considered before surgery [Shepherd, 1991] to demonstrate a 
NSCLC component. 
 New metachronous tumours appearing two years after a SCLC successfully treated 
patients could be second primary NSCLC and after a complete re-staging should be 
surgically resected even if histology can not be obtained preoperatively [Anraku, 2006] 
5.2 Patient selection criteria and choice of surgical procedure 
If a diagnosis is obtained preoperatively, pathologists should exclude any possible 
coexisting NSCLC component. Even more than in NSCLC, accurate staging is crucial before 
planning surgery in fit patients, as discussed before. Toronto Group demonstrated better 5-
year survival (18% vs 6%) in patients without mediastinal nodes involvement 
preoperatively [Shepherd, 1991]; in a recent phase II trial on surgery after induction 
chemotherapy only patients who achieved complete nodal downstaging had a fair survival. 
Mediastinoscopy and eventually re-mediastinoscopy after primary treatment is therefore 
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recommended to detect nodal involvement which is microscopic and subclinical in a 
considerable percentage of patients. This matter accounts for discordance between clinical 
and pathological staging in SCLC. 
If a SCLC is diagnosed in operative theatre at frozen section of specimens, radical resection 
(preferably lobectomy) is recommended if intraoperative histological examination of 
mediastinal lymph nodes does not reveal metastasis; however, surgery can be proposed to 
patients with mediastinal nodes micrometastasis  if they can easily tolerate the procedure. 
Sublobar resections are recommended in less fit patients or in presence of nodal 
involvement. 
6. Targeting the complex biology of SCLC 
First cytogenetic studies, dated 1982, found that a deletion on chromosome 3p was present 
in 95% of SCLC [Whang, 1982]. This chromosomal region contains tumour-suppressor genes 
relevant to the pathogenesis of the tumour e.g. RARβ [Naylor 1987, Kok 1987] and FITH 
[Franklin, 2010]. The 3p loss alone is not specific of SCLC, since it is frequent encountered 
also in other tumours. Thanks to the high-throughput technology as comparative genomic 
hybridization (CGH) and gene expression arrays, researchers discovered that in 90% of 
SCLC samples, the most frequent sites of chromosome loss are 3p, 5q and 13q, the last 
determining the loss of  retinoblastoma gene (RB1) [Ried, 1994]. Mutation studies on biology 
of SCLC showed that this type of tumour has frequent mutation in the gene encoding for 
p53 protein (TP53) [Hanahan, 200] but rarely presents mutation in the tyrosine-kinase 
signalling gene including KRAS and EGFR [Franklin, 2010], which are actually the most 
known pathways with larger number of active drugs (mainly tested in lung 
adenocarcinomas). 
Targeted cancer therapies are drugs or antibodies that block the growth and the spread of 
cancer by interfering with specific molecules involved in tumour growth and progression. 
These therapies are being studied for use alone, in combination with other targeted 
therapies, and in combination with other cancer treatments, such as chemotherapy. By 
blocking signals that make cancer cell grow and replicate, targeted cancer therapies can help 
to stop cancer progression and may induce cancer cell death through apoptosis. 
To give an example the PI3K/AKT/mTOR intracellular pathway is chronically activated in 
SCLC through inactivating mutations in PTEN gene and this activation pathway correlates 
with sensitivity to Everolimus in vitro [Marinov, 2009]. Furthermore, the amplification of 
BCL-2 genes seems to be correlate with the sensitivity to the highly potent small-molecule 
called ABT-737 suggesting that patients with bcl-2 protein over expression, may have some 
benefits from bcl-2 inhibitors [Olejniczak, 2007]. In SCLC cell lines, microRNA and gene-
expression signatures of chemo-resistance have been described [Guo, 2010] and several 
inhibitors of growth factor pathways implicated in SCLC are in clinical development 
(NCT00896752); the compound PD173074 induces apoptosis in vitro and in vivo in SCLC by 
inhibition of  FGF2 signalling [Pardo, 2009].  
The targeting of specific molecules has been already studied in several trials, even though 
with limited success. One of the emerging need in clinical research dealing with SCLC is 
inadequacy of preclinical models of disease used to date. Cancer-cell-line-based xenograft 
models employed as standard testing ground especially for drugs have revealed as a 
surrogate of disease. In vitro activity level is then weakly predictable of clinical efficacy thus 
explaining the high rates of failure of new drugs tested in clinical studies. Human cancers 
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cells, compared to cancer-cell cultures, grow up in hypoxic and nutrient-poor complex 
environments which promotes continue selection of  more aggressive cell-clones. This 
explains the reason why cell-line-based SCLC xenografts tend to grow as relatively indolent 
tumours, while corresponding human disease is characterized by aggressive clinical and 
biological behaviour. 
Moreover, as for standard chemotherapy, the use of a single molecular target drug in such 
complex malignancy as SCLC, is wrong. The inhibition of multiple targets or the 
combination with standard chemotherapic agents are likely to have greater potential. The 
customizing of therapy with novel agent to individual patient's characteristics is becoming 
the most beneficial approach to treatment of SCLC. In addition to new agents, biomarkers of 
chemosensitivity need be identified to efficaciously assess single agents for relapse after 
first-line therapy or as a maintenance therapy in placebo-controlled, randomised designs. 
Several studies have identified genes or proteins in lung cancer whose expression levels are 
associated with response to antitumor drugs. The breast cancer resistant protein (BCRP), is 
one of  the ABC transporters reported to be associated with resistance to anticancer drugs 
like doxorubicin, irinotecan, mitoxantrone, and its expression  was found to be associated 
with a poor clinical outcome in SCLC patients undergoing chemotherapy [Kim, 2009]. 
Chiappori et al. reported that RRM1 and Topo2 alpha proteins expression are biomarkers of 
chemotherapeutic efficacy in SCLC [Chiappori, 2010] and, recently, Usuda et al. 
demonstrated that the expression levels of Klotho protein was correlated with the prognosis 
following resection in SCLC patients [Usuda, 2011]. These results are encouraging; however, 
this findings need to be incorporated into common signatures for individual therapies and 
further tested in prospective clinical trials. Of course, biostatistical concerns still exist for 
predicting response to drugs as for predicting patient prognosis. 
7. Conclusions 
Although the incidence of SCLC has been steadily decreasing over time, it continues to 
represent a relevant problem of public health due to its aggressive clinical behaviour and 
the lack of effective therapies; it is considered one of the most elusive cancers. Twenty-five 
years ago it was considered to be the next malignancy added to the list of curable cancers, 
because of the effectiveness of several chemotherapeutic agents and radiation therapy, and 
the discover of central nervous system sanctuary, which would require distinct treatment.  
Conversely, despite active and ongoing research involving novel approaches to treat SCLC, 
few discovers had a successful translation in clinical practice over the past 25 years, with 
cumulative improvement of only 15% in survival which remains dismal and moreover 
seems to have now reached a plateau. 
7.1 Current evidences 
Over the last 25 years, few landmarks in therapy have been provided by clinical trials 
focused on LS-SCLC. Minimal progress was noted in ES-SCLC. 
Main strategies that demonstrated able to add small but significant improvements in 
survival can be summarized in the followings: 
 Advantage of addition of radiotherapy to chemotherapy:  The defining report, Cancer 
and Leukemia Group B (CALGB) 8083 [14], published in the New England Journal of 
Medicine, showed, for patients with LS-SCLC, a local control, failure-free survival, and 
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overall survival benefit with the addition of thoracic radiation to chemotherapy using a 
cyclophosphamide and doxorubicin–based regimen. At 2 years, only 13% of patients 
who received chemotherapy alone maintained local control, compared with 54% of 
patients receiving chest radiotherapy. Although the likelihood of relapse in the chest 
may be reduced by up to 50% when thoracic irradiation is administered after 
chemotherapy, 20–36% of patients will have local recurrence even after combined 
modality treatment [12,13]. An analysis of the site of first relapse demonstrated that, 
even for patients who have achieved clinical complete response, the primary tumour 
bed and hilar or mediastinal lymph node areas are the most frequent single sites of 
failure [Elliott, 1987]. Failure to achieve control at the primary site remains the most 
important obstacle to cure in patients with limited SCLC [Shepherd, 1991]. 
 superiority of twice-daily radiation therapy over daily fractionation: hyperfractioning 
radiation therapy was defined and experimented in order to respond to the need of 
improve local control of disease, which remains a serious issue in non-surgical 
managed patients 
 advantage of prophylactic central nervous system radiation (PCI) in all responding 
patients (also with ES-SCLC)  
7.2 Take home messages 
There are other recommendations without strong evidence, but for which there is general 
agreement: 
 Resection is a reasonable option as initial treatments for early stages T1-2N0-M0 
patients: if preoperative diagnosis of SCLC has been obtained, nodal or distant 
metastasis must be excluded using by either non invasive or invasive staging, avoiding 
futile thoracotomies. Induction chemo-radiotherapy did not demonstrated superior to 
adjuvant setting. In any other stage of presentation, surgery is contemplated only in 
clinical trials. 
 Clinical understaging is frequent in SCLC (concordance with pathological stage is 
only 58% in IASLC database) and common criteria of resectability often fails to predict 
complete resections in SCLC, due to propensity to spread through peribronchial 
lymphatic vessels to regional lymph-nodes. Introduction and more liberal use of EUS in 
flexible bronchoscopy or mediastinoscopy may help to rule out patients with 
micrometastasis not amenable of surgical resection 
 Surgery improves local control of disease if radical resection is achieved. Local failure 
rates vary in literature from 0 to 15%, which is considerably lesser than 35-50% reported 
for chemo-therapy with twice-daily radiation therapy (the standard of care, to date) 
[Pijls-Johannesma et al., 2007; Turrisi et al., 1999]. In resected specimens after concurrent 
CT with HfRTx, Eberhardt found persistence of vital disease at the primary site 
[Eberhardt & Korfee, 2003]. However, there is no evidence, to date, that this translates 
in an improvement of overall and disease-free survival, which could eventually derive 
from progresses in systemic treatments. 
7.3 Challenge to systemic disease 
Since the overwhelming majority of patients with LD-SCLC have subclinical metastatic foci 
at the time of diagnosis, chemotherapy is an essential part of multimodal treatment to 
control systemic disease. 
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Cytotoxic drugs active in SCLC discovered in the early 1980s remains a standard of care at 
present. Advances in supportive care and technical advances in radiation therapy have 
allowed the application of therapies with less toxicity and well tolerated by most patients. 
Fall in treatment-related deaths implies an improvement on survival (compared to history of 
20-yrs ago) which is actually difficult to be discriminated by the true prolongation of 
survival due to change in natural history of disease. 
At now, most of ongoing clinical trials deal with various combination of active cytotoxic 
agents, but it has become evident that only small improvements in survival should be 
expected by such protocols. The issue is not spectrum of active drugs, as is the case in 
melanoma, for example but rather the rapid development of drug resistance and the failure 
of second-line therapy, especially in case of no response to primary treatment or early 
relapse of disease (< 3 months). Therefore clinical research on SCLC is shifting towards 
target-therapy, although most efforts have been and are still spent on lung adenocarcinoma, 
because its arise in incidence makes it more attractive in terms of cost/effectiveness of 
research.  
Another issue in SCLC-related researches is paradoxically the introduction of fine-needle 
aspiration techniques rather than biopsy for histologic diagnosis: this has dramatically 
diminished the material available for studying compared with other lung cancers and other 
epithelial tumors. 
7.4 Current perspectives: “Time to fish or cut bait” 
“Immortalization” of old randomized trials which refused surgery in multimodal treatment of 
SCLC in others era is no more acceptable today. A different staging system, lack or routine 
diagnostic tools and some evident weak points make these milestones anachronistic at now. 
However, due to small number of cases and bias in selection of patients, retrospective series 
starts to carry a small usefulness in adding greater evidence in any type of treatment not 
contemplated in current guidelines. Meta-analyses too seem not to be reliable on studies 
that encompass sometimes two or three decades: lack of homogeneity between cohorts 
characteristics, staging system, diagnostic tools and type of treatments administered are a 
major issue to significance of results reported. 
As brilliantly stated from Shepherd in comment to another retrospective trial on SEER 
database [Yu, 2010] “it is time to fish or cut bait”: thoracic oncologists have to seriously face 
the question of role of surgery in multimodal approach to SCLC,: if they decide to fish, a 
large multi-center, international prospective randomized trial seem the only feasible option 
to achieve powerful statistical results [Shepherd, 2010]. Trial should accrue a large number 
of patients in a limited period of time with strict eligibility criteria in order to ensure as more 
homogeneity as possible among centres regarding patients selection, staging criteria and 
treatment modalities. In the forthcoming seventh edition of the TNM staging system, the 
IASLC has recommended to apply TNM stratification to SCLC in future clinical trials on 
LD-SCLC. At least one of the arm should be treated with chemo-radiation therapy followed 
by PCI, which represents actually the standard of care. 
The small number of patients eligible for surgical trials makes accrual extremely slow, so 
that 3 trials started before 2003 have not been published yet (Essen Thoracic Oncology 
Group, West Japan Thoracic Oncology group, German Multicenter Randomised Trial). 
Meanwhile advances in comprehension of molecular biology of SCLC will perhaps improve 
systemic control of disease, supporting and not excluding the role of surgery as the most 
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powerful tool of cytoreduction local strategy even in more locally advanced disease in order 
to eliminate potential residual clones of resistant cells. It seems in fact still REMOTE the 
possibility discover of definitive systemic therapy capable of achieve complete local and 
distant, permanent remission of disease 
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